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Background: Safety of vaccines remains a cornerstone of building public trust on the use of these cost-effective
and life-saving public health interventions. In some settings, particularly Sub-Saharan Africa, there is a high prevalence
of HIV infection and a high burden of vaccine-preventable diseases. There is evidence suggesting that the immunity
induced by some commonly used vaccines is not durable in HIV-infected persons, and therefore, repeated vaccination
may be considered to ensure optimal vaccine-induced immunity in this population. However, some vaccines,
particularly the live vaccines, may be unsafe in HIV-infected persons. There is lack of evidence on the safety
profile of commonly used vaccines among HIV-infected persons. We are therefore conducting a systematic
review to assess the safety profile of routine vaccines administered to HIV-infected persons.
Methods/Design: We will select studies conducted in any setting where licensed and effective vaccines were
administered to HIV-infected persons. We will search for eligible studies in PubMed, Web of Science, Cochrane
Central Register of Controlled Trials (CENTRAL), Scopus, Africa-Wide, PDQ-Evidence and CINAHL as well as reference
lists of relevant publications. We will screen search outputs, select studies and extract data in duplicate, resolving
discrepancies by discussion and consensus.
Discussion: Globally, immunisation is a major public health strategy to mitigate morbidity and mortality caused by
various infectious disease-causing agents. In general, there are efforts to increase vaccination coverage worldwide, and
for these efforts to be successful, safety of the vaccines is paramount, even among people living with HIV, who in some
situations may require repeated vaccination. Results from this systematic review will be discussed in the context of the
safety of routine vaccines among HIV-infected persons. From the safety perspective, we will also discuss whether repeat
vaccination strategies may be feasible among HIV-infected persons.
Systematic review registration: PROSPERO CRD42014009794.Background
Effective and safe vaccines against diseases such as se-
vere forms of tuberculosis, diphtheria, tetanus, pertussis,
mumps, measles, rubella, pneumococcus, polio, yellow
fever, and rotavirus, among others, contribute towards
preventing 2.5 million childhood deaths annually through
vaccination [1]. Additionally, vaccines targeting adoles-
cents (10–19 years old) such as human papillomavirus
(HPV) vaccines, meningococcal conjugate vaccines, influ-
enza vaccines as well as booster vaccines of measles,* Correspondence: bkagina@yahoo.com
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unless otherwise stated.tetanus, diphtheria and pertussis are routinely used in
some settings to mitigate vaccine-preventable diseases
[2]. Therefore, public health strategies that target the
vaccination of children, adolescents as well as adults
are more likely to yield success in elimination of vaccine-
preventable diseases as opposed to strategies that target
children only [3].
The goal of any effective vaccine is to induce a long-
lasting specific immunity that confers protection against
the targeted pathogen. Some reports suggest that indi-
viduals with underlying HIV infection may have attenu-
ated vaccine-induced immunity, including lower and
loss of anamnestic responses, which could reduce the ef-
fectiveness of the vaccines [4]. Furthermore, a systematic
review by Kerneis et al. showed that long-term immunityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kagina et al. Systematic Reviews 2014, 3:101 Page 2 of 6
http://www.systematicreviewsjournal.com/content/3/1/101induced by many routinely used vaccines is diminished
to non-protective levels in HIV-infected persons [5]. As
a result, a repeat vaccination could be considered for
certain vaccines in this population to ensure maintained
protection against vaccine-preventable diseases. For ex-
ample, the Advisory Committee on Immunization Prac-
tices (ACIP) recommended revaccination with measles,
mumps and rubella (MMR) vaccine to HIV-infected per-
sons over 12 months of age and with no evidence of im-
munosuppression [6].
The majority of HIV infections in infants and children
occur early in life through vertical transmission from the
mother, while in older age groups, HIV is acquired
through horizontal transmission. HIV infection is preva-
lent in low-income and middle-income countries (LMICs)
[7]. The LMICs account for about 85% of the global popu-
lation and contribute to a disproportionately high burden
of vaccine-preventable diseases (VPDs). Factors contribut-
ing to the high burden of the VPDs in LMICs include low
rates of vaccine uptake [8,9], high rates of malnutrition
[10], as well as high prevalence of underlying HIV infec-
tion; [7] all of which may result in lowering vaccine effect-
iveness in these settings.
The role of underlying immunosuppressive conditions
contributing to reducing vaccine effectiveness is corrob-
orated in some LMICs where a high burden of VPDs,
despite reasonably high vaccination coverage, is reported
[11]. Following the synthesised evidence by Kerneis
et al., which showed that HIV infection results in dimin-
ished vaccine-induced immunity in the long term [5],
our interest is to evaluate the feasibility of a repeat
vaccination among HIV-infected persons from a safety
perspective. We hypothesise that for some vaccines,
HIV infection will compromise the safety profile and
therefore, revaccination among children, adolescents and
adults could be risky. This suggests that revaccination
with some vaccines may not be feasible among HIV-
infected persons. To test our hypothesis, we are conduct-
ing a systematic review. Our aim is to assess the safety
profile of routinely used vaccines administered to HIV-
infected persons.
The WHO recommends administration of most vac-
cines delivered through EPI to both HIV-uninfected and
HIV-infected persons, with the exception of BCG where
risk-benefit analysis needs to be considered. As far as
we know, there is no systematic review on the safety
profiles of many routinely used vaccines in HIV-infected
persons.
Primary objective
 The primary objective of this study is to compare
the safety profile of the WHO-recommended
vaccines administered to HIV-infected persons.Secondary objective
 The secondary aim is to compare the safety
profile of the WHO-recommended vaccines
re-administered to HIV-infected persons.
Methods/Design
Types of studies
We will consider only primary studies with the following
designs:
 Interventional studies: individually randomised
controlled trials (RCTs), cluster-randomised controlled
trials (cRCT) and non-randomised control trials.
 Observational studies: case series, interrupted time
series (ITS), controlled before-and-after (CBA)
studies, cohort studies, case–control studies,
cross-sectional studies and ecological studies.
Review articles, letters and editorials will be excluded.
Study settings
We will include studies conducted in any setting and in any
country, whether low-, middle- or high-income countries.
Population
We will include children, adolescents and adults for this
systematic review. Children will be defined as age cat-
egory of 0–9 years. Adolescents will be defined as age
category of 10–19 years, while adults will be defined as
those above 19 years of age.
We will only include studies in which participants
were HIV-infected or both HIV-infected and HIV-
uninfected. Included studies must have used defined and
standard assays or tests to determine the HIV infection.
Studies that evaluated the safety of the vaccines prior to
licensure will also be included provided the vaccines
were licensed later.
Types of interventions
Participants of studies included in this review must have
received any WHO-recommended vaccine (Table 1).
The vaccines to be included in this review are as follows:
 Oral polio vaccine (OPV) and/or inactivated polio
vaccine (IPV)
 Bacillus Calmette-Guérin (BCG)
 Diphtheria, pertussis and tetanus (DTP)—we will
include both whole cell and acellular pertussis
 Rotavirus vaccine (RV)
 Hepatitis B vaccine (HBV)
 Hepatitis A vaccine (HAV)
 Measles vaccine or measles in combination with
mumps and rubella (MMR) vaccine
Table 1 Summary of WHO position papers on the recommended vaccines
Antigen Children Adolescents Adults
BCG
Hepatitis B 3–4 doses 3 doses for high-risk groups if not previously vaccinated
Polio 3–4 doses
DTP 3 doses, booster (DTP), 1–6 years of age Booster Booster
Haemophilus influenzae type b (Hib) 3 doses with DTP
Pneumococcal (conjugate) 3 doses with DTP
Rotavirus 2 or 3 doses with DTP
Measles 2 doses
Rubella 1 dose 1 dose, adolescent girls if not previously vaccinated
HPV 3 doses Girls
Japanese encephalitis 1 dose, booster dose after 1 year Booster dose after every 3 years up to 10–15 years of age
Yellow fever 1 dose
Tick-borne encephalitis 3 doses
Typhoid 1 dose or 3 doses (dependent on vaccine), booster dose after 3–7 years
Cholera 3 doses with booster after every 6 months, 2 doses for children of
6 years and older/adults with booster every 2nd year
Meningococcal 1 dose (1–29 years)
Men A conjugate 2 doses (2–11 months) with booster 1 year after 1st dose
Men C conjugate 2 doses (9–23 months), 1 dose (2 years and older)
Quadrivalent conjugate
Hepatitis B At least 1 dose at 1 year or older
Rabies 3 doses
Mumps 2 doses
Influenza (inactivated) 2 doses, revaccinate annually 1 dose from 9 years of age, revaccinate annually
Vaccines for varicella virus, herpes zoster virus and pneumococcal (polysaccharides) are not in this table, but will be included in the review. This table is adapted
from the Summary of WHO Position Papers—Recommendations for Routine Immunization.
1 (http://www.who.int/immunization/policy/Immunization_routine_table1.pdf?ua=1).
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 Pneumococcal conjugate vaccine (PCV)
 Pneumococcal polysaccharide vaccine
 Meningococcal vaccine
 Human papillomavirus vaccine (HPV)








 Herpes zoster virus vaccine
Type of outcome measures
The primary outcome of this review is the establishment
of the safety profile of licensed vaccines administered to
HIV-infected individuals and the assessment of vaccine-
related adverse events (frequency and duration of mild
to severe adverse events).Search methods for identification of studies
A comprehensive search strategy has been developed for
searching electronic and other resources. We will search
the following electronic databases for primary studies:
PubMed, Web of Science, Cochrane Central Register of
Controlled Trials (CENTRAL), Scopus, Africa-Wide, PDQ-
Evidence and CINAHL. The electronic search will use the
common terms describing the safety of these routine vac-
cines. We will search for published articles with no lan-
guage restriction. The detailed electronic search strategy
for PubMed is provided in Table 2. In addition, we will
search reference lists of relevant reviews and all potentially
eligible studies.
Data collection and analysis
Selection of studies
Two authors will independently screen the search outputs
for potentially eligible studies, compare their results and
resolve disagreements by discussion and consensus. The
two authors will then independently go through the full
text of all potentially eligible studies to assess whether the
Table 2 Proposed search strategy and search outputs for PubMed database
Query
#5 (#3 AND #4)
#4 (HIV infected OR HIV positive OR HIV OR HIV exposed uninfected OR HEU)
#3 (#1 AND #2)
#2 (Persons OR Participants OR Newborns OR babies OR infants OR children OR adolescents OR teenage OR young adults OR youth OR adults)
#1 (Safety of OPV OR safety of IPV OR safety of polio vaccine OR effectiveness of OPV OR effectiveness of IPV OR effectiveness of polio vaccine OR
efficacy of OPV OR efficacy of IPV OR efficacy of polio vaccine OR Safety of BCG vaccine OR safety of Bacillus Calmette Guérin vaccine OR
effectiveness of BCG vaccine OR effectiveness of Bacillus Calmette Guérin vaccine OR efficacy of BCG vaccine OR efficacy Bacillus Calmette Guérin
vaccine OR Safety of DTP vaccine OR safety of Diphtheria vaccine OR Safety of Pertussis vaccine OR safety of Tetanus vaccine OR effectiveness of
DTP vaccine OR effectiveness of Diphtheria vaccine OR effectiveness of Pertussis vaccine OR effectiveness of Tetanus vaccine OR efficacy of DTP
vaccine OR efficacy of Diphtheria vaccine OR efficacy of Pertussis vaccine OR efficacy of Tetanus vaccine OR Safety of RV vaccine OR safety of
Rotavirus vaccine OR effectiveness of RV vaccine OR effectiveness of Rotavirus vaccine OR efficacy of RV vaccine OR efficacy of Rotavirus vaccine
OR Safety of HBV OR safety of Hepatitis B vaccine OR effectiveness of HBV OR effectiveness of Hepatitis B vaccine OR efficacy of HBV OR efficacy
of Hepatitis B vaccine OR Safety of HAV OR safety of Hepatitis A vaccine OR effectiveness of HAV OR effectiveness of Hepatitis A vaccine OR
efficacy of HAV OR efficacy of Hepatitis A vaccine OR Safety of MMR vaccine OR safety of Measles vaccine OR safety of Mumps vaccine OR safety
of Rubella vaccine OR effectiveness of MMR vaccine OR effectiveness of Measles vaccine OR effectiveness of Mumps vaccine OR effectiveness of
Rubella vaccine OR efficacy of MMR vaccine OR efficacy of Measles vaccine OR efficacy of Mumps vaccine OR efficacy of Rubella vaccine OR
Safety of YF vaccine OR safety of Yellow fever vaccine OR effectiveness of YF vaccine OR effectiveness of Yellow fever vaccine OR efficacy of YF
vaccine OR efficacy of Yellow fever vaccine OR Safety of PCV OR safety of Pneumococcal conjugate vaccine OR effectiveness of PCV OR
effectiveness of Pneumococcal conjugate vaccine OR efficacy of PCV OR efficacy of Pneumococcal conjugate vaccine OR Safety of MC vaccine
OR safety of Meningococcal vaccine OR effectiveness of MC vaccine OR effectiveness of Meningococcal vaccine OR efficacy of MC vaccine OR
efficacy of Meningococcal vaccine OR Safety of HPV vaccine OR safety of Human Papilloma Virus vaccine OR effectiveness of HPV vaccine OR
effectiveness of Human Papilloma Virus vaccine OR efficacy of HPV vaccine OR efficacy of Human Papilloma Virus vaccine OR safety of JE vaccine
OR safety of Japanese Encephalitis vaccine OR effectiveness of JE vaccine OR efficacy of JE vaccine OR safety of Hib vaccine OR safety of
Haemophilus influenzae type b vaccine OR effectiveness of Hib vaccine OR efficacy of Hib vaccine OR safety of inactivated influenza vaccine OR
effectiveness of inactivated influenza vaccine OR efficacy of inactivated influenza vaccine OR safety of cholera vaccine OR effectiveness of cholera
vaccine OR efficacy of cholera vaccine OR safety of typhoid vaccine OR effectiveness of typhoid vaccine OR efficacy of typhoid vaccine OR safety
of rabies vaccine OR effectiveness of rabies vaccine OR efficacy of rabies vaccine OR safety of Tick-Bone Encephalitis vaccine OR effectiveness of
Tick-Bone Encephalitis vaccine OR efficacy of Tick-Bone Encephalitis vaccine OR safety of varicella vaccine OR effectiveness of varicella vaccine OR
efficacy of varicella vaccine OR safety of herpes zoster virus vaccine OR effectiveness of herpes zoster virus vaccine OR efficacy of herpes zoster
virus vaccine OR safety of pneumococcal polysaccharide vaccine OR effectiveness of pneumococcal polysaccharide vaccine OR efficacy of
pneumococcal polysaccharide vaccine)
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design, setting, population, intervention and outcomes.
Discrepancies in the list of eligible studies between the
two authors will be resolved through discussion and
consensus.
Data extraction
A structured and standardised data collection form has
been developed for extracting data from the selected
studies. The form will capture key study characteristics,
including methods, participants’ characteristics and out-
comes (Additional file 1: Table S1). Prior to use, the ex-
traction form will be piloted on at least four included
studies identified randomly from the list of included
studies, and if need be, modifications will be made. For
the recently (2010 onwards) published literature, if any
selected study has incomplete or missing data, we will
contact the authors for more information. If the authors
provide no additional information, a decision will be
taken by at least two authors on the inclusion of the
study in the final analyses.
Assessment of risk of bias in included studies
We will use a similar approach to the one we previously
described [12]. The quality of studies will be assessedusing the Cochrane Collaboration’s tool for assessing
risk of bias [13] for experimental studies and the Scot-
tish Intercollegiate Guidelines Network (SIGN) checklist
for other study designs [14].
Grading the quality of evidence and strength of
recommendations
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system to
assess the quality of evidence [15] (based on the clinical
methods used to assess adverse events).
Data synthesis
We will express the result of each study as a risk ratio
(RR) with its corresponding 95% confidence intervals for
dichotomous data or median difference (MD) with its
standard deviation (SD) for continuous data. For each
study, the adverse events in the vaccine arm will be
compared with adverse events in the control arm with
use of RRs and 95% confidence intervals (CIs). Pooled
RRs and 95% CIs will be calculated for the effect of each
vaccine on development of adverse events following im-
munisation using random effects model. Secondary ana-
lysis will compare the rates of adverse events following
immunisation in HIV-infected versus HIV-uninfected
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conducted to investigate the rates of adverse events fol-
lowing revaccination relative to primary vaccination. We
will conduct meta-analysis for studies that have used the
same age group of participants, similar adverse events
reporting method, same vaccines, time points post vacci-
nations and outcome measures where homogeneity of
data allows. Heterogeneity will be assessed using the
chi-squared test of homogeneity and quantified using the
I-squared statistic (with 95% uncertainty intervals). Where
possible, mixed effects models will be used to adjust for
confounding factors such as co-morbidities and HIV-
related protein and energy malnutrition (PEM).
Assessment of heterogeneity
We anticipate substantial variation in study results due
to differences in the study design, method of assessing
adverse events, age group (children, adolescents and
adults), study settings (low-income, middle-income, and
high-income countries) and risk of bias. We will exam-
ine statistical heterogeneity between study results using
the chi-squared test of homogeneity (with significance
defined at the alpha level of 10%) and quantify any stat-
istical heterogeneity between study results using the
I-squared statistic [13].
Assessment of reporting biases
A funnel plot will be used to investigate the risk of pub-
lication bias by vaccine, provided 10 or more studies are
included in the analysis for each vaccine related adverse
event evaluated. The funnel plot will be critically exam-
ined for asymmetry.
Sensitivity analysis
We will conduct sensitivity analysis to establish if the
meta-analysis results are influenced by clinical and meth-
odological diversities. Subgroup analysis based on the CD4
cell counts and the viral load may be conducted if we have
a sufficient number of studies reporting these variables.
Discussion
We anticipate that our systematic review results will es-
tablish whether persons infected with HIV have an in-
creased risk of adverse events following vaccination with
routine vaccines. Our results may be used to guide vac-
cinologists in developing better vaccination strategies for
HIV-infected populations. The results will be critical in
the context of optimising current vaccination strategies
in the context of HIV infection in any given setting [16].Additional file
Additional file 1: Table S1. Proposed data extraction form.Competing interests
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